CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 97 enrolled
Drug / intervention
Escitalopramdrug
Likely dose
Escitalopram 10 to 30 mg per day for 12 weeksAI-extracted
Key inclusion· 3
  • ✓Meets DSM-IV criteria for major depressive disorder (depressed subjects)
  • ✓Hamilton Depression Rating Scale (17 items) score >16 at study entry
  • ✓For healthy volunteers: no lifetime history of major neurological, medical, psychiatric disorder, or head injury
Key exclusion· 11
  • ✕Current suicidal ideation that may make study participation unsafe
  • ✕Current serious or unstable medical illness (cardiovascular, kidney, liver, respiratory, endocrine, neurologic, or blood-related disease)
  • ✕History of seizure disorder
  • ✕History of or current psychotic disorder, bipolar disorder, or substance dependence disorder within 12 months of study entry

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00183677
NCT00183677Phase 4Completed
CompareCT.gov

Biochemical Brain Changes Correlated With the Antidepressant Effect of Escitalopram: A Magnetic Resonance Spectroscopic Imaging Study

Massachusetts General Hospital·interventional·Posted Sep 16, 2005·Updated Jan 4, 2017

In Brief

A Phase 4 clinical trial evaluating Escitalopram for Depression. Completed, enrolled 97 participants across 1 site.

Detailed Summary

This study will evaluate changes in brain energy metabolism due to treatment with escitalopram in people with major depressive disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 16, 2005
Enrollment StartJul 1, 2003
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 20.8 years ago

Interventions

Escitalopramdrug

Escitalopram 10 to 30 mg per day for 12 weeks